Partner Joseph Reisman was quoted in “The IP dangers in life sciences collaborations and how to avoid them,” which was published by IAM.
Excerpt: “To anticipate just who owns the patent is insufficient in these contexts,” remarks Joseph Reisman of Knobbe Martens. “What you need in the pharma and certainly the biologics space is to think one step further ahead. You have to imagine the different scenarios and build those into IP acquisition, prosecution and enforcement provisions.”
Read the full article here >> (Subscription Required)
